MetaCap

Harvard Bioscience (HBIO) vs Standard BioTools (LAB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Harvard Bioscience (HBIO) has outperformed Standard BioTools (LAB) over the past year, gaining 37.5% versus a loss of 54.3%. Over five years, LAB leads with a -86.5% price change compared with -87.4% for HBIO. Standard BioTools is the larger company by market cap ($249.1 million vs $39.6 million), about 6.3 times the size.

Harvard Bioscience converts more of its revenue into profit, with a net margin of -65.5% versus -87.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

HBIO+37.46%LAB-54.28%
+59%-4%-67%
Nov 21, 20251 yearNov 20, 2026
HBIO-88.36%LAB-85.95%
+9%-46%-101%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

HBIO versus LAB key metrics
MetricHBIOLAB
Share price$8.66$0.631
Market cap$39.60M$249.11M
1-day change-0.23%+2.82%
YTD return+29.25%-50.70%
1-year return+37.46%-54.28%
5-year return-87.45%-86.55%
Forward P/E16.34—
EPS (TTM)$-2.59$-0.09
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$86.55M$85.33M
Revenue growth (YoY)-8.06%-6.24%
Net income (latest FY)$-56.70M$-74.90M
Gross margin57.67%49.86%
Operating margin-56.13%-129.20%
Net margin-65.51%-87.77%
52-week high$10.20$1.72
52-week low$4.00$0.39
Distance from 52-week high-15.10%-63.31%
Analyst consensusnonenone
Avg. price target upside-13.39%+113.95%
Average volume21.82K1.16M
Shares outstanding4.57M394.79M
Employees316385
SectorIndustrialsIndustrials
IndustryBiotechnology: Laboratory Analytical InstrumentsBiotechnology: Laboratory Analytical Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Standard BioTools is about 6.3 times larger than Harvard Bioscience by market value ($249.11M vs $39.60M).
  • HBIO has outperformed LAB by 91.7 percentage points over the past year.
  • Harvard Bioscience is more profitable, keeping -65.5 cents of every revenue dollar as net income versus -87.8 cents for Standard BioTools.

About Harvard Bioscience

HBIO stock →

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally.

Industrials · Biotechnology: Laboratory Analytical Instruments · 316 employees

About Standard BioTools

LAB stock →

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments.

Industrials · Biotechnology: Laboratory Analytical Instruments · 385 employees

HBIO vs LAB FAQ

Which is bigger, Harvard Bioscience or Standard BioTools?

Standard BioTools (LAB) is larger, with a market capitalization of $249.11M compared with $39.60M for Harvard Bioscience (HBIO).

Which stock has performed better over the past year, HBIO or LAB?

HBIO returned +37.46% over the past 12 months, compared with -54.28% for LAB (price return, excluding dividends). Past performance does not predict future results.

Are Harvard Bioscience and Standard BioTools in the same industry?

Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.

More comparisons